Metabolic syndrome as a predictor of type 2 diabetes, and its clinical interpretations and usefulness

Abstract

Metabolic syndrome is defined as a cluster of glucose intolerance, hypertension, dyslipidemia and central obesity with insulin resistance as the source of pathogenesis. Although several different combinations of criteria have been used to define metabolic syndrome, a recently published consensus recommends the use of ethnic-specific criteria, including waist circumference as an indicator of central obesity, triglyceride and high-density lipoprotein (HDL) cholesterol as indicators of dyslipidemia, and blood pressure greater than 130/85 mmHg. The definition of dysglycemia, and whether central obesity and insulin resistance are essential components remain controversial. Regardless of the definition, the prevalence of metabolic syndrome is increasing in Western and Asian countries, particularly in developing areas undergoing rapid socioenvironmental changes. Numerous clinical trials have shown that metabolic syndrome is an important risk factor for cardiovascular disease (CVD), type 2 diabetes mellitus and all-cause mortality. Therefore, metabolic syndrome might be useful as a practical tool to predict these two major metabolic disorders. Comprehensive management of risk factors is very important to the improvement of personal and public health. However, recent studies have focused on the role metabolic syndrome plays as a risk factor for CVD; its importance in the prediction of incident diabetes is frequently overlooked. In the present review, we summarize the known evidence supporting metabolic syndrome as a predictor for type 2 diabetes mellitus and CVD. Additionally, we suggest how metabolic syndrome might be useful in clinical practice, especially for the prediction of diabetes. (J Diabetes Invest,

The role of β-blockers in patients with metabolic syndrome and hypertension

“…A metabolikus szindrómát centrális típusú elhízás és a szénhidrát-anyagcsere zavara (IFG = impaired fasting glucose, kóros éhomi vércukorszint, IGT = impaired glucose tolerance, csökkent glükóztolerancia vagy 2-es típusú diabetes mellitus), hypertonia, dyslipidaemia jellemzi, amelynek hátterében a feltételezések szerint inzulinrezisztencia áll [3]. Egyes vizsgálatok szerint a metabolikus szindróma háromszorosára emeli a coronariabetegség és a stroke kockázatát (P<0,001), valamint szignifikánsan emeli a CV-mortalitást is (P<0,001) [4].…”

Untitled

“…The MS has been widely associated with incident type 2 diabetes (T2D) and cardiovascular diseases (CVD) 1,2 . Development of the MS is influenced by genetic and environmental factors and their interaction with each other 3,4 .…”

Untitled

“…It has been associated with increased risk of type 2 diabetes and cardiovascular disease (CVD) 1,2 . MS is one of the most problem of world proportions affecting developed and underdeveloped countries in a rapidly progressive way 3,4 .…”